Shan Liang
National Center for Biotechnology Information, NLM, NIH
The Cy5.5-labeled and gadolinium (Gd(III))-chelated chitosan nanoparticles, abbreviated as Cy5.5-CNP-Gd(III), are an optical/magnetic resonance (MR) dual imaging agent synthesized by Nam et al. for multimodality imaging of tumors (1). The idea of using multiple modalities in a single imaging session comes from the fact that modalities with high sensitivity have relatively poor resolution, while those with high resolution have relatively poor sensitivity (2, 3). Integration of multiple modalities in imaging would take the advantages of each modality and allow better characterization of diseases and disease processes (4, 5). To date, the most successful hybrid system is derived from the fusion of positron emission tomography (PET) and computed tomography (CT) (5-8). PET is highly sensitive and allows three-dimensional images that show the concentration and location of the radiolabeled tracers of interest, while CT provides high-resolution imaging of the anatomical structures. Because of limited soft-tissue contrast and high X-ray radiation that accompanies CT imaging, considerable effort has been invested in recent years toward development of PET/magnetic resonance imaging (MRI) hybrid systems in an attempt to generate combined functional and morphological images with excellent soft tissue contrast, good spatial resolution of the anatomy, and accurate temporal and spatial image fusion (9-11). In contrast, systems integrated with optical techniques have not been investigated as extensively. Considering the advantages of multichannel imaging with single or multiple probes and the low cost of studying reporter gene expression in animal models, optical imaging integrated with other modalities may provide information at the cellular and molecular levels, which is critical in preclinical studies (1, 2, 12). Development of hybrid imaging technology has triggered great effort in probe development to boost the benefits of hybrid instrument technology (12-15). In the case of optical/MRI probe design, the challenge is turned around to incorporate enough paramagnetic ions for detection by the relatively low sensitivity of MRI. Nam et al. have developed a dual imaging probe (Cy5.5-CNP-Gd(III)) with water-soluble glycol chitosan and the probes were preferably accumulated within the tumor xenografts (1). Chitosan has been frequently used to make nanoparticles carrying imaging reporters as well as therapeutic agents (1, 12, 15). Generally, the positively charged chitosan polymer can coat around a nanoparticle core by electrostatic adsorption, and other components are embedded in the chitosan matrix during the coating process. All components can also be entrapped simultaneously in the chitosan matrix.
Cy5.5标记且钆(Gd(III))螯合的壳聚糖纳米颗粒,简称为Cy5.5-CNP-Gd(III),是Nam等人合成的一种用于肿瘤多模态成像的光学/磁共振(MR)双功能成像剂(1)。在单次成像过程中使用多种模态的想法源于这样一个事实,即高灵敏度的模态分辨率相对较差,而高分辨率的模态灵敏度相对较差(2, 3)。成像中多种模态的整合将利用每种模态的优势,并能更好地表征疾病和疾病过程(4, 5)。迄今为止,最成功的混合系统源自正电子发射断层扫描(PET)和计算机断层扫描(CT)的融合(5 - 8)。PET具有高灵敏度,能生成显示感兴趣的放射性标记示踪剂浓度和位置的三维图像,而CT提供解剖结构的高分辨率成像。由于CT成像存在软组织对比度有限和X射线辐射高的问题,近年来人们投入了大量精力来开发PET/磁共振成像(MRI)混合系统,试图生成具有出色软组织对比度、良好解剖结构空间分辨率以及准确时间和空间图像融合的功能与形态相结合的图像(9 - 11)。相比之下,与光学技术集成的系统尚未得到广泛研究。考虑到使用单探针或多探针进行多通道成像的优势以及在动物模型中研究报告基因表达的低成本,与其他模态集成的光学成像可能在细胞和分子水平提供信息,这在临床前研究中至关重要(1, 2, 12)。混合成像技术的发展引发了在探针开发方面的巨大努力,以提升混合仪器技术的优势(12 - 15)。在光学/MRI探针设计方面,挑战在于要纳入足够的顺磁性离子,以便通过灵敏度相对较低的MRI进行检测。Nam等人用水溶性乙二醇壳聚糖开发了一种双功能成像探针(Cy5.5-CNP-Gd(III)),且这些探针优先在异种移植肿瘤中聚集(1)。壳聚糖经常被用于制备携带成像报告分子以及治疗剂的纳米颗粒(1, 12, 15)。一般来说,带正电荷的壳聚糖聚合物可以通过静电吸附包裹在纳米颗粒核心周围,在包裹过程中其他成分被嵌入壳聚糖基质中。所有成分也可以同时被困在壳聚糖基质中。